Home > Insider Trading > Filing (0001415889-24-015673)

Filing Details

Accession Number:: 0001415889-24-015673
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-05 19:19:57
Reporting Period:: 2024-06-03

Accepted Time:: 2024-06-05 19:19:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817713	Janux Therapeutics Inc.	JANX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1652901	Avalon Ventures Xi, L.p.	1134 Kline Street La Jolla CA 92037	No	No	No	No
1844550	Avalon Bioventures Spv I, L.p.	1134 Kline Street La Jolla CA 92037	No	No	Yes	No
1873935	Avalon Bioventures I, Lp	1134 Kline Street La Jolla CA 92037	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-06-03	677,279	$54.75	3,271,216	No	4	S	Direct
Common Stock	Disposition	2024-06-03	131,196	$54.75	633,673	No	4	S	Indirect	By Avalon BioVentures I, LP
Common Stock	Disposition	2024-06-03	691,525	$54.75	3,340,018	No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	By Avalon BioVentures I, LP
No	4	S	Indirect	By Avalon BioVentures SPV I, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the shares held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the shares held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the shares held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these shares except to the extent of its respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.